Optimizing use of SGLT2 inhibitors and other evidence-based therapies to improve outcomes in patients with type 2 diabetes and chronic kidney disease: An opportunity for pharmacists

被引：6
|
作者：
Neumiller, Joshua J. [1 ]
Shubrook, Jay H. [2 ]
Manley, Tom [3 ]
Alicic, Radica Z. [4 ,5 ,6 ]
Tuttle, Katherine R. [4 ,7 ,8 ]
机构：
[1] Washington State Univ, Coll Pharm & Pharmaceut Sci, Spokane, WA 99202 USA
[2] Touro Univ, Primary Care Dept, Vallejo, CA USA
[3] Natl Kidney Fdn, New York, NY USA
[4] Providence Hlth Care, Providence Med Res Ctr, Spokane, WA USA
[5] Univ Washington, Div Med, Spokane, WA USA
[6] Univ Washington, Div Med, Seattle, WA 98195 USA
[7] Univ Washington, Div Nephrol, Kidney Res Inst, Spokane, WA USA
[8] Univ Washington, Div Nephrol, Kidney Res Inst, Seattle, WA USA
来源：
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2022年 / 79卷 / 01期
关键词：
diabetic kidney disease; kidney outcomes; multidisciplinary care; pharmacist intervention; SGLT2; inhibitor; INTERVENTIONS; MANAGEMENT; MORTALITY; CARE;
D O I：
10.1093/ajhp/zxab271
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：E65 / E70
页数：6
相关论文
共 50 条
  • [1] Association of SGLT2 Inhibitors and Other Second Line Therapies With Incident Chronic Kidney Disease in Patients With Type 2 Diabetes
    Wang, Wendy
    Drawz, Paul
    Chow, Lisa
    Chen, Lin Y.
    Walker, Rob F.
    Norby, Faye L.
    Lutsey, Pamela L.
    CIRCULATION, 2024, 149
  • [2] Type 2 Diabetes and Chronic Kidney Disease: An Opportunity for Pharmacists to Improve Outcomes
    Neumiller, Joshua J.
    St Peter, Wendy L.
    Shubrook, Jay H.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (05)
  • [3] Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
    Kelly, Michael S.
    Lewis, Jelena
    Huntsberry, Ashley M.
    Dea, Lauren
    Portillo, Ivan
    POSTGRADUATE MEDICINE, 2019, 131 (01) : 31 - 42
  • [4] SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
    Kanduri, Swetha R.
    Kovvuru, Karthik
    Hansrivijit, Panupong
    Thongprayoon, Charat
    Vallabhajosyula, Saraschandra
    Pivovarova, Aleksandra I.
    Chewcharat, Api
    Garla, Vishnu
    Medaura, Juan
    Cheungpasitporn, Wisit
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09)
  • [5] The effects of the SGLT2 inhibitors on the Japanese type 2 diabetes patients with chronic kidney disease
    Kobayashi, K.
    Sato, K.
    Hatori, N.
    Miyakawa, M.
    Toyoda, M.
    DIABETOLOGIA, 2017, 60 : S418 - S418
  • [6] Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
    Scheen, Andre J.
    CLINICAL PHARMACOKINETICS, 2015, 54 (07) : 691 - 708
  • [7] The Kidney Effects of the SGLT2 Inhibitors on the Japanese Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease
    Kobayashi, Kazuo
    Toyoda, Masao
    Hatori, Nobuo
    Sakai, Hiroyuki
    Furuki, Takayuki
    Tamura, Kouichi
    Miyakawa, Masaaki
    DIABETES, 2019, 68
  • [8] Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
    André J. Scheen
    Clinical Pharmacokinetics, 2015, 54 : 691 - 708
  • [9] SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
    David C. Wheeler
    June James
    Dipesh Patel
    Adie Viljoen
    Amar Ali
    Marc Evans
    Kevin Fernando
    Debbie Hicks
    Nicola Milne
    Philip Newland-Jones
    John Wilding
    Diabetes Therapy, 2020, 11 : 2757 - 2774
  • [10] SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
    Wheeler, David C.
    James, June
    Patel, Dipesh
    Viljoen, Adie
    Ali, Amar
    Evans, Marc
    Fernando, Kevin
    Hicks, Debbie
    Milne, Nicola
    Newland-Jones, Philip
    Wilding, John
    DIABETES THERAPY, 2020, 11 (12) : 2757 - 2774
12345